Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroconversion and occupational exposure of employees at a Swiss university hospital: A large longitudinal cohort study.


Journal

Infection control and hospital epidemiology
ISSN: 1559-6834
Titre abrégé: Infect Control Hosp Epidemiol
Pays: United States
ID NLM: 8804099

Informations de publication

Date de publication:
03 2022
Historique:
pubmed: 20 3 2021
medline: 1 4 2022
entrez: 19 3 2021
Statut: ppublish

Résumé

The dynamics of coronavirus disease 2019 (COVID-19) seroconversion of hospital employees are understudied. We measured the proportion of seroconverted employees and evaluated risk factors for seroconversion during the first pandemic wave. In this prospective cohort study, we recruited Geneva University Hospitals employees and sampled them 3 times, every 3 weeks from March 30 to June 12, 2020. We measured the proportion of seroconverted employees and determined prevalence ratios of risk factors for seroconversion using multivariate mixed-effects Poisson regression models. Overall, 3,421 participants (29% of all employees) were included, with 92% follow-up. The proportion of seroconverted employees increased from 4.4% (95% confidence interval [CI], 3.7%-5.1%) at baseline to 8.5% [(95% CI, 7.6%-9.5%) at the last visit. The proportions of seroconverted employees working in COVID-19 geriatrics and rehabilitation (G&R) wards (32.3%) and non-COVID-19 G&R wards (12.3%) were higher compared to office workers (4.9%) at the last visit. Only nursing assistants had a significantly higher risk of seroconversion compared to office workers (11.7% vs 4.9%; P = .006). Significant risk factors for seroconversion included the use of public transportation (adjusted prevalence ratio, 1.59; 95% CI, 1.25-2.03), known community exposure to severe acute respiratory coronavirus virus 2 (2.80; 95% CI, 2.22-3.54), working in a ward with a nosocomial COVID outbreak (2.93; 95% CI, 2.27-3.79), and working in a COVID-19 G&R ward (3.47; 95% CI, 2.45-4.91) or a non-COVID-19 G&R ward (1.96; 95% CI, 1.46-2.63). We observed an association between reported use of respirators and lower risk of seroconversion (0.73; 95% CI, 0.55-0.96). Additional preventive measures should be implemented to protect employees in G&R wards. Randomized trials on the protective effect of respirators are urgently needed.

Sections du résumé

BACKGROUND
The dynamics of coronavirus disease 2019 (COVID-19) seroconversion of hospital employees are understudied. We measured the proportion of seroconverted employees and evaluated risk factors for seroconversion during the first pandemic wave.
METHODS
In this prospective cohort study, we recruited Geneva University Hospitals employees and sampled them 3 times, every 3 weeks from March 30 to June 12, 2020. We measured the proportion of seroconverted employees and determined prevalence ratios of risk factors for seroconversion using multivariate mixed-effects Poisson regression models.
RESULTS
Overall, 3,421 participants (29% of all employees) were included, with 92% follow-up. The proportion of seroconverted employees increased from 4.4% (95% confidence interval [CI], 3.7%-5.1%) at baseline to 8.5% [(95% CI, 7.6%-9.5%) at the last visit. The proportions of seroconverted employees working in COVID-19 geriatrics and rehabilitation (G&R) wards (32.3%) and non-COVID-19 G&R wards (12.3%) were higher compared to office workers (4.9%) at the last visit. Only nursing assistants had a significantly higher risk of seroconversion compared to office workers (11.7% vs 4.9%; P = .006). Significant risk factors for seroconversion included the use of public transportation (adjusted prevalence ratio, 1.59; 95% CI, 1.25-2.03), known community exposure to severe acute respiratory coronavirus virus 2 (2.80; 95% CI, 2.22-3.54), working in a ward with a nosocomial COVID outbreak (2.93; 95% CI, 2.27-3.79), and working in a COVID-19 G&R ward (3.47; 95% CI, 2.45-4.91) or a non-COVID-19 G&R ward (1.96; 95% CI, 1.46-2.63). We observed an association between reported use of respirators and lower risk of seroconversion (0.73; 95% CI, 0.55-0.96).
CONCLUSION
Additional preventive measures should be implemented to protect employees in G&R wards. Randomized trials on the protective effect of respirators are urgently needed.

Identifiants

pubmed: 33736734
pii: S0899823X21001173
doi: 10.1017/ice.2021.117
pmc: PMC8082127
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

326-333

Subventions

Organisme : Medical Research Council
ID : MC_PC_19012
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom

Auteurs

Romain Martischang (R)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.

Anne Iten (A)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.

Isabelle Arm (I)

Division of Laboratory Medicine, Department of Diagnostics, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.

Mohamed Abbas (M)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.

Benjamin Meyer (B)

Center for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.

Sabine Yerly (S)

Division of Laboratory Medicine, Department of Diagnostics, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.
Division of Infectious Diseases, Department of Medicine, University of Geneva Hospitals, Geneva, Switzerland.

Isabella Eckerle (I)

Division of Laboratory Medicine, Department of Diagnostics, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.
Division of Infectious Diseases, Department of Medicine, University of Geneva Hospitals, Geneva, Switzerland.
Geneva Center for Emerging Viral Diseases, University of Geneva Hospitals, Geneva, Switzerland.

Jacques Pralong (J)

Occupational Health Service, University of Geneva Hospitals, Geneva, Switzerland.
Pulmonary Division, University of Geneva Hospitals, Geneva, Switzerland.

Julien Sauser (J)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.

Jean-Claude Suard (JC)

Occupational Health Service, University of Geneva Hospitals, Geneva, Switzerland.

Laurent Kaiser (L)

Division of Laboratory Medicine, Department of Diagnostics, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.
Division of Infectious Diseases, Department of Medicine, University of Geneva Hospitals, Geneva, Switzerland.
Geneva Center for Emerging Viral Diseases, University of Geneva Hospitals, Geneva, Switzerland.

Didier Pittet (D)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.

Stephan Harbarth (S)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH